Join
Live feed
·
INSIDERFilingvia Quantisnow
Cadrenal Therapeutics Inc. logo

Chairman, CEO and Interim CFO Pham Quang X sold $13,110 worth of shares (4,126 units at $3.18) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 128,589 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
CVKD· Cadrenal Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CVKD (Cadrenal Therapeutics Inc.) and more on Quantisnow.

Chairman, CEO and Interim CFO Pham Quang X sold $13,110 worth of shares (4,126 units at $3.18) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 128,589 units (SEC Form 4) | Quantisnow